Company Analysis AbCellera Biologics Inc.
1. Summary
Advantages
- Price (2.82 $) is less than fair price (9.68 $)
- Current debt level 5.2% is below 100% and has decreased over 5 years from 29.36%.
Disadvantages
- Dividends (0%) are below the sector average (0.5399%).
- The stock's return over the last year (-44.49%) is lower than the sector average (-43.68%).
- The company's current efficiency (ROE=-12.7%) is lower than the sector average (ROE=9.78%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| AbCellera Biologics Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -18.7% | -25.1% | -5.3% |
| 90 days | -6% | -45.3% | -0.3% |
| 1 year | -44.5% | -43.7% | 18.9% |
ABCL vs Sector: AbCellera Biologics Inc. has slightly underperformed the "Healthcare" sector by -0.8078% over the past year.
ABCL vs Market: AbCellera Biologics Inc. has significantly underperformed the market by -63.42% over the past year.
Stable price: ABCL is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ABCL with weekly volatility of -0.8555% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (2.82 $) is lower than the fair price (9.68 $).
Price significantly below the fair price: The current price (2.82 $) is 243.3% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (18.83) is lower than that of the sector as a whole (61.47).
P/E vs Market: The company's P/E (18.83) is lower than that of the market as a whole (51.48).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.45) is lower than that of the sector as a whole (4.79).
P/BV vs Market: The company's P/BV (1.45) is lower than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (43.88) is higher than that of the sector as a whole (33.58).
P/S vs Market: The company's P/S indicator (43.88) is higher than that of the market as a whole (10.3).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-8.39) is higher than that of the sector as a whole (-17.26).
EV/Ebitda vs Market: The company's EV/Ebitda (-8.39) is lower than that of the market as a whole (29.6).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -44.63% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-44.63%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (11.51%).
5.4. ROE
ROE vs Sector: The company's ROE (-12.7%) is lower than that of the sector as a whole (9.78%).
ROE vs Market: The company's ROE (-12.7%) is lower than that of the market as a whole (8.95%).
5.5. ROA
ROA vs Sector: The company's ROA (-9.84%) is lower than that of the sector as a whole (0.33%).
ROA vs Market: The company's ROA (-9.84%) is lower than that of the market as a whole (6.3%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (18.42%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (18.42%) is higher than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5399%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
